Gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) in Degenerative Knee Osteoarthritis Patients: Lessons and Responders from a Multicenter Randomized Placebo-Controlled Double-Blind Clinical Trial

Table 4

Treatment effect as measured at baseline, week 2, week 4, and week 8 (N = 80).

Characteristic	Baseline^†	Week 2^†	Mean difference^†	value^b	Week 4^†	Mean difference^†	value^b	Week 8^†	Mean difference^†	value^b
VAS
GCB	57.95 (52.16, 63.74)	52.55 (46.04, 59.06)	−5.40 (−7.92, −2.88)	<0.0001	54.03 (47.33, 60.72)	−3.93 (−7.21, −0.64)	0.0196	47.17 (40.00, 55.33)	−10.78 (−19.67, −1.90)	0.0174
Placebo	60.30 (54.35, 66.25)	52.76 (45.74, 59.78)	−7.54 (−12.92, −2.17)	0.0061	61.47 (53.79, 69.05)	1.12 (−6.15, 8.39)	0.7615	50.17 (43.91, 56.43)	−10.13 (−17.92, −2.33)	0.0109
value^a	0.5688	0.7002			0.1881			0.6368
K-WOMAC
GCB	44.23 (37.89, 50.56)	41.30 (35.79, 46.81)	−2.93 (−5.02, −0.83)	0.0064	41.40 (35.02, 47.78)	−2.83 (−4.80, 0.85)	0.0054	40.61 (33.35, 47.87)	−3.61 (−8.86, 1.63)	0.1768
Placebo	46.73 (41.57, 51.88)	43.76 (38.71, 48.81)	−2.97 (−6.62, 0.69)	0.1114	43.76 (37.67, 49.82)	−2.96 (−8.46, 2.54)	0.2914	37.78 (31.46, 44.10)	−8.95 (−14.61, −3.29)	0.0020
value^a	0.5375	0.7571			0.8599			0.2103
EQ-5D
GCB	0.73 (0.69, 0.77)	0.72 (0.68, 0.76)	0 (−0.02, 0.01)	0.5930	0.73 (0.68, 0.77)	0 (−0.02, 0.01)	0.7971	0.75 (0.72, 0.79)	0.03 (−0.01, 0.06)	0.0955
Placebo	0.71 (0.67, 0.75)	0.72 (0.69, 0.75)	0.02 (−0.02, 0.06)	0.3946	0.74 (0.71, 0.77)	0.04 (−0.01, 0.08)	0.1596	0.76 (0.73, 0.8)	0.06 (0, 0.11)	0.0337
value^a	0.4594	0.6055			0.3395			0.5466

^†Data expressed as 95% confidence interval. ^a value was calculated from analysis of covariance with baseline score as a covariate. ^b value was calculated from the paired t-test. Significant difference. GCB, Gyejigachulbutang; VAS, visual analogue scale; K-WOMAC, Korean Western Ontario and McMaster Universities Osteoarthritis Index; EQ-5D, European Quality of life Five Dimensions questionnaire.